BioXcel Therapeutics Inc (BTAI) saw an uptrend of 15.37% in the recent trading with $5.48 being its most recent. The current price level -58.99% lower than the highest price of $13.36 marked by the stock while trading over the past 52-weeks, whereas it is 368.38% higher than the lowest price of $1.17 the company dropped to over past 52-weeks. The latest news story.BTAI appeared in (Benzinga) under the title “3 Supercharged Stocks Flashing Strong Momentum Signals”.
Squeezing the time span to 30 day period shows us the stock is currently trading -32.18% below one month high and is +321.54% above of the lowest during that time. Looking into the simple moving average, BioXcel Therapeutics Inc (BTAI)’s stock stands at a SMA-50 of $2.35 while that of 5-day is reading $5.81.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more.stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and BTAI’s SMA-200 as of now is $3.89.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 8 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
BioXcel Therapeutics Inc Earnings – What Happened With BTAI
Coming around sales and income figures.BTAI Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. BioXcel Therapeutics Inc (BTAI) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 33.33% for net revenue.
BTAI – BioXcel Therapeutics Inc Stock Earnings Estimates
The perspective of BioXcel Therapeutics Inc (NASDAQ:BTAI)’s current quarter earnings identifies that analysts are in consensus over the estimate of -7.68 for stock’s EPS in the current quarter. BioXcel Therapeutics Inc (BTAI) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 33.33% for net revenue. Company’s EPS for the last quarter was -5.12.
BioXcel Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 14.56 million. BTAI does have institutional investors; and they hold 4.34% of the stock.
As.2024-06-30, ARMISTICE CAPITAL, LLC was the top most holder in BioXcel Therapeutics Inc (NASDAQ:BTAI) with an ownership of 2.99 million shares of the company or 1.1178 of the stake worth $3.82 million. The filing also reveals FMR LLC as the second largest holder in the company with a control over 0.8252 of the outstanding shares. Its stake is worth $2.82 million for having 2.21 million shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 0.3632 of the outstanding shares. With this there are now 36.0 institutions which have possession in BTAI’s shares.
Key Metrics forBTAI
Technical Analysis of BioXcel Therapeutics Inc (NASDAQ:BTAI) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for BioXcel Therapeutics Inc (BTAI), we notice that the stock’s 20-day average volume is at 22,668,480 shares and 50% of short term indicators are suggesting the stock as Buy. Its 50-day average volume of 9,257,756 shares. And to end, BTAI’s 100-day average volume is 4,747,583 shares with 50% of the long-term indicators pointing towards Buy for the stock.
